SYNLAB AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.54 EUR | 0.00% |
|
-3.30% | -7.45% |
| Apr. 15 | SYNLAB AG(XTRA:SYAB) dropped from S&P Global BMI Index | CI |
| Apr. 05 | Tranche Update on SYNLAB AG's Equity Buyback Plan announced on September 22, 2022. | CI |
| Sales 2024 * | 2.79B 2.98B | Sales 2025 * | 3.06B 3.26B | Capitalization | 2.33B 2.48B |
|---|---|---|---|---|---|
| Net income 2024 * | 89M 94.76M | Net income 2025 * | 87M 92.63M | EV / Sales 2024 * | 1.41 x |
| Net Debt 2024 * | 1.6B 1.71B | Net Debt 2025 * | 1.67B 1.78B | EV / Sales 2025 * | 1.31 x |
| P/E ratio 2024 * |
26.4
x | P/E ratio 2025 * |
26.8
x | Employees | 23,538 |
| Yield 2024 * |
1.16% | Yield 2025 * |
1.99% | Free-Float | 34.33% |
More Fundamentals
* Assessed data
More news
Latest transcript on SYNLAB AG
| 1 day | -0.38% | ||
| 1 week | -3.30% | ||
| Current month | -2.67% | ||
| 1 month | -8.25% | ||
| 3 months | -10.51% | ||
| 6 months | +6.72% | ||
| Current year | -7.45% |
1 week
10.54
10.76
1 month
10.0011.37
Current year
10.0012.30
1 year
8.0212.30
3 years
6.6924.60
5 years
6.6924.60
10 years
6.6924.60
| Managers | Title | Age | Since |
|---|---|---|---|
Mathieu Floreani
CEO | Chief Executive Officer | 56 | 21-01-25 |
Sami Badarani
DFI | Director of Finance/CFO | 61 | 21-01-25 |
Henrik Andreasen
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Ebsworth
CHM | Chairman | 69 | 21-01-10 |
| Founder | 63 | 97-12-31 | |
Peter Catterall
BRD | Director/Board Member | 55 | 21-01-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 10.56 | +0.19% | 0 |
| 24-04-18 | 10.54 | -0.19% | 0 |
| 24-04-17 | 10.56 | -1.86% | 216 |
| 24-04-16 | 10.76 | +0.75% | 0 |
| 24-04-15 | 10.68 | -2.20% | 0 |
Delayed Quote Deutsche Boerse AG, April 19, 2024 at 02:06 am EDT
More quotes
Synlab AG is a Germany based clinical laboratory and medical diagnostic services provider. The Company is engaged in laboratory services for human and veterinary medicine, as well as environmental analysis.
Calendar
2024-05-07
- Q1 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
10.58
EUR
Average target price
12.57
EUR
Spread / Average Target
+18.78%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.11% | 8.02B | |
| +36.93% | 3.51B | |
| -26.72% | 2.97B | |
| -13.47% | 2.23B | |
| -14.89% | 1.76B | |
| -23.12% | 1.44B | |
| -39.19% | 1.25B | |
| -11.20% | 1.11B | |
| +3.67% | 1.07B |
- Stock Market
- Equities
- SYAB Stock
- SYAB Stock
